Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q1 2024 ▲▼ | Q2 2024 ▲▼ | Change ▲▼ | Q1 2024 ▲▼ | Q2 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Dyne Therapeutics, Inc.(DYN) | 7,845,364 | 7,845,364 | 0 | $222.73M | $276.86M | 40.83% | +$54.13M |
| Newamsterdam Pharma Company ORDINARY SHARES | 11,831,461 | 11,831,461 | 0 | $279.81M | $227.28M | 33.52% | -$52.53M |
| Engene Holdings Inc COM | 8,677,951 | 8,677,951 | 0 | $147.09M | $81.83M | 12.07% | -$65.26M |
| Replimune Group, Inc.(REPL) | 4,866,449 | 4,866,449 | 0 | $39.76M | $43.80M | 6.46% | +$4.04M |
| Bicycle Therapeutics PlcADS | 0 | 2,122,892 | +2,122,892 | $0 | $42.97M | 6.34% | +$42.97M |
| Engene Holdings IncW EXP 10 31 2028 *W EXP 10/31/202 | 2,878,148 | 2,878,148 | 0 | $14.97M | $3.42M | 0.51% | -$11.54M |
| Achilles Therapeutics PlcADS | 2,390,050 | 2,390,050 | 0 | $2.99M | $1.95M | 0.29% | -$1.04M |